Worldwide Glioma Diagnosis and Treatment Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2023

 Glioma Diagnosis and Treatment Market: By Type (Primary, Secondary) Diagnosis (CT, MRI) Treatment (Surgery, Chemotherapy), Grade (Low, High, Recurrent), Location (Supratentorial, Infratentorial), End-User (Hospitals & Clinics) – Global Forecast Till 2023

Market Scenario

A Glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain.

Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.

According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.

Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5877

Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.

The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.

Key Players

Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.

Segmentation

Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.

North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.

The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.

Regional Analysis

The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.

The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  

Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/glioma-diagnosis-treatment-market-5877

Asthma Device Market Leading Asthma Device Market Key Developments Trends, Analysis And Forecasts Till 2023

 Market Synopsis of Global Asthma Devices Market

Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease. Increasing prevalence of asthma is one of the major drivers for the market growth. According to the World Health Organization in 2017, approximately 235 million people suffered from asthma. Moreover, it was estimated that in 2015, the disease killed approximately 383 million patients around the globe. Additionally, rising healthcare expenditures and increasing awareness fuel the market growth. However, long treatment procedures and low per capita income followed by lack of favorable reimbursement policies in the developing countries will restrain the market growth during the forecast period.

The global asthma devices market size is expected to grow at an approximate CAGR of 4.3% during the forecast period. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1624

Segmentation

The global copd and asthma devices market is segmented on the basis of type, technology, and end users.

On the basis of the type, the market is segmented into inhalers, nebulizers, and others. The inhalers segment is sub-segmented into metered-dose inhalers and dry powder inhalers. The metered-dose inhalers segment, by inhalers, is further categorized into standard pressurized metered-dose inhalers, breath-activated pressurized metered-dose inhalers, metered-dose inhalers with a spacer, and others. The nebulizers segment is sub-segmented into compressor nebulizers, ultrasonic nebulizers, mesh nebulizers, and others.

On the basis of technology, the market is segmented into manually operated inhaler devices, digitally operated inhaler devices, and others.

On the basis of end users, the market is segmented into hospital, clinics, retail pharmacies, and others.

Regional Analysis 

The Americas dominate the global asthma devices market owing to a well-developed healthcare sector and huge patient population for asthma diseases. According to the Centres for Disease Control and Prevention, in 2015, approximately, 7.8% of the total population in the U.S. was identified for the presence of asthma. Moreover, changing lifestyle and increasing healthcare expenditure fuels the market growth. Additionally, the presence of global players like Merck & Co., Inc. and Baxter, and others boost market growth during the forecast period. 

Europe is the second largest asthma devices market owing to a well-developed healthcare infrastructure and huge patient population. Moreover, government support for research & development and rising healthcare expenditures fuel the market growth. According to a study published in the Asthma Research and Practice journal in 2017, the yearly estimated cost for all the asthmatics per patient is about USD 1,900. Additionally, the presence of the developed economies like the U.K, Germany, and France within the region boosts the market growth. 

Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China. According to a study of the Indian Chest Society in 2015, 300 million people suffered from asthma worldwide and about a tenth of its share is in India. Moreover, as per the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020. Moreover, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax along boosts the market growth. 

On the other hand, the Middle East & Africa holds the least share of the global asthma devices market due to the presence of poor economy, especially within the African region. The absence of the developed healthcare sector and stringent government policies restrain the market growth within the African region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures. 

Key players for global asthma devices market

GlaxoSmithKline plc. (Europe), Merck & Co., Inc. (U.S.), 3M (U.S.), Aristopharma Ltd. (Asia Pacific), SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific), AstraZeneca (Europe), Baxter. (U.S.), Boehringer Ingelheim GmbH (Europe), Koninklijke Philips N.V. (Europe), and others.Top of Form

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asthma-devices-market-1624

Microbiology Testing Market Professional Overview 2020-2023 With Major Vendors Size, Shares And Worldwide Demand

 Microbiology Testing Market Research Report: Information by Product Type (Instruments, Chemicals & Reagents, Consumables & Accessories and others), Application (Gastrointestinal Infections, Respiratory Infections, Urinary Tract Infections, Sexually Transmitted Infections and others), End User (Hospital Associate Laboratory, Independent Laboratory and Academic and Research Institutes) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2023

Market Scenario

The Global Microbiology Testing Market Size is expected to register 10.4% CAGR and is anticipated to reach USD 5409.1 6 Million by 2023. Microbiology testing services help to lower the potential damage risk by microbes and to ensure that the microbiology quality of the products is maintained. The microbial testing technique includes chemical, biological, biochemical, or molecular methods to quantify and identify microbes.

Technological advancements, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are the major drivers propelling market growth. However, erroneous results and high cost of reagents and instruments may constrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/697

Key Players

The prominent players in the global microbiology testing market are, Beckman Coulter, Inc. (a subsidiary of Danaher Corp), BioMérieux SA, Thermo Fisher Scientific Inc., Cepheid (a subsidiary of Danaher), and F. Hoffmann-La Roche Ltd.

Some of the key strategies followed by the players operating in the global microbiology testing market were innovation, product development, acquisition, and expansion.

Market Dynamics

Technological advancements are expected to drive the growth of the market. For instance, according to the data published by the National Centre for Health Statistics in 2017, there were around 9,272 cases of tuberculosis infectious disease. Additionally, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are likely to support market growth. On the other hand, erroneous results and high cost of reagents and instruments are anticipated to hamper the market growth.

Segmentation

The global microbiology testing market has been segmented into product type, application, and end user. 

Based on type, the global market has been segmented into instruments, chemicals & reagents, consumables & accessories, and others. The instruments segment accounted for a market value of USD 954.9 million in 2016.

Based on application, the global market has been segmented into gastrointestinal infections, respiratory infections, urinary tract infections, sexually transmitted infections, and others.

Based on end user, the global market has been segmented into hospital associate laboratory, independent laboratory, and academic and research institutes.

Regional Analysis

The global microbiology testing market, based on region, is segmented into North Americas, Europe, Asia-Pacific, and the Middle East & Africa.

North America is estimated to dominate the global microbiology testing market during the forecast period. This can be attributed to the rapid adoption of advanced products and techniques. The European market for microbiology testing is expected to be the second-largest during the forecast period. Increasing innovation and changing laboratory practices is expected to boost the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing market due to increasing funding for R&D, developing healthcare infrastructure, growing awareness about microbiology testing, government initiatives to improve public health, and growing investments by major players. Moreover, in the region, South Korea accounted for a market share of 9.2% in 2016.

The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, and limited availability to equipment.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697

Antihypertensive Drugs Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2020 To 2023

 According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the anti-hypertensive drugs market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.

Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.

The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2347

Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.

Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.

Segmentation

The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;

Segmentation By Pharmacological Class               : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.

Segmentation By Hypertension Type                      : Comprises Systemic and Pulmonary Hypertension Drugs and other.

Segmentation By Disease Source                              : Comprises Primary and Secondary.

Segmentation By Regions                                            : Comprises Geographical regions - North America, Europe, APAC, including Anti-Hypertensive Drugs Market in India and Rest of the World.

Regional Analysis

The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.

The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.

The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.

Key Players

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. are some of the prominent players at the forefront of competition in the Global Market of Anti-Hypertensive Drugs and are profiled in MRFR Analysis.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

Worldwide Molecular Modelling Market Ready To Set Outstanding Growth From 2020 To 2023

 Market Scenario

Molecular modelling comprises an array of computational techniques used in creation, manipulation, and representation of the various reactions and structures of molecules. Molecular Modelling applications included drug discovery and development but have since extended into computational chemistry and materials science. Rising use of molecular modelling by scientists to run multiple simulations can expedite the drug development process considerably.

The global molecular modelling market share is anticipated to expand at a 15.16% CAGR from 2018 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Investments in R&D by pharmaceutical and biotechnology companies and prevalence of chronic diseases are factors certain to spur market growth over the forecast period.

According to the Brookings Private Sector Global Health R&D Project, nearly USD 159.9 Bn has been dispensed for healthcare R&D in developed and developing regions. Out of which, the majority can be credited to pharmaceutical companies. The booming biosimilars and biologics industry is bound to propel the market demand in the coming years. But the high R&D expenditure can impede market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4330

Report Overview

The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts make highly astute projections regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global molecular modelling market segmented by product, application, end-user, and region. Trends and opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.

Segment Overview

Products in the molecular modelling market include software and services. Major applications include drug discovery, drug development, and others. Drug discovery is sub-segmented into direct drug design, indirect drug design, and molecular mimicry. End-users of the market include research centers and academic institutions, pharmaceutical and biotechnology companies, and others.

The segments covered in the report are analyzed with respect to four major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “molecular modelling” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.

Competitive Landscape

Some of the key players in the molecular modelling market include Cresset, Acellera Ltd., Schrödinger, LLC, Optibrium, BioSolve-IT, Simulations Plus, Inc., Chemical Computing Group, Certara, L.P, OpenEye Scientific Software, Dassault Systèmes, Cambridge Crystallographic Data Centre, and others. New product launches and clinical trials are used to gauge the success of drugs. Various strategies such as acquisitions, partnerships, joint ventures, and distribution agreements are used by these players to gain a major share in the market.

The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are discussed in granular detail.

Opportunity:

Countries situated near the equator have become the budding ground for many chronic diseases such as chagas, dengue, leprosy, and rabies due to problematic climactic conditions forcing these countries to employ the latest advancements into their system. Governments of developing countries have initiated education programs and projects such as the Janala Project in Bangladesh, ProjectABC in Nigeria, Tostan in Senegal, Yoza in South Africa, and BridgeIT in Tanzania, and others to create awareness regarding the conditions and healthcare IT tools.

Regional Analysis

The Americas dominates the global molecular modelling market owing to well-developed technology, increasing prevalence of the people suffering from cardiovascular diseases, and increasing government support for research & development. Furthermore, high healthcare expenditure and increasing R&D activities have fuelled the growth of the market in this region.

Europe holds the second position in the global molecular modelling market, which is followed by Asia Pacific. It is expected that the government support for research & development and availability of funds for research will drive the market. Asia Pacific is the fastest growing molecular modelling market due to the presence of rapidly growing economy, developing healthcare technology, increasing healthcare expenditure, and huge patient pool.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/molecular-modelling-market-4330 

Covid-19 Impact On Telehealth Market Growing Trends, Demand And Business Outlook 2020 To 2024

 Market Research Future (MRFR) collected data on several factors including implications of covid-19 impact on microbiome sequencing services market and demographic challenges, showed how it could move forward in the coming years.

Global Telehealth Market size is expected to register a CAGR of 22.74% to reach USD 16,173.8 Million by 2024. Telehealth is the use of digital information and communication technologies to access healthcare services remotely for the management of health. Telehealth connects patients to fundamental healthcare services through remote monitoring, video conferencing, electronic consultations, and wireless communications. Factors such as the increasing prevalence of chronic diseases, the rise in geriatric population, and the shortage of physicians are the major drivers propelling the telehealth market growth. However, privacy and security concerns and stringent government rules for telehealth services could hamper market growth during the forecast period.

Impact 0f COVID-19 on the Telehealth Market

1.1 A HISTORICAL PERSPECTIVE

It did not take novel coronavirus for the telehealth industry to start gaining traction among healthcare providers and patients. Telehealth was already experiencing significant momentum and growth prior to this public health emergency, particularly over the past few years as the technology has become more streamlined and young tech-savvy generation is gaining interest in this care model. The appetite for telehealth is growing, but many consumers are confused or unsure about its availability.

We have observed the massive impact of novel coronavirus on people’s lives over the last five months. It has also impacted various industries across the globe, eventually affecting the global economy. Some industries have experienced negative growth, whereas some industries have experienced tremendous demand and have generated massive revenues in this period. Covid 19 Impact on Telehealth marke trends is the one of the positive impact sector on global industry

Telehealth Market Dynamics

Telehealth could be effectively utilized for the diagnosis, treatment, and supportive care of chronic diseases such as diabetes and cancer. Chronic diseases reduce a person’s quality of life, especially if left undiagnosed or untreated. According to data by the Government of Canada, in 2017, about 2.3 million people aged 12 and older were diagnosed with diabetes. Additionally, according to the press release by Chiron Health published in June 2016, chronic diseases such as heart disease, stroke, cancer, depression, type 2 diabetes, obesity, and arthritis affected an estimated 117 million people in the Americas. Telehealth can be used to address the rising demand for healthcare services for cancer, diabetes, and other diseases in developing regions. Thus, the high prevalence of such diseases is estimated to drive market growth during the forecast period.

Telehealth Market Key Players

The prominent players in the global telehealth market are Boston Scientific Corporation (US), AMD Global Telemedicine Inc. (US), Siemens (Germany), Allscripts Healthcare Solutions (US), Right Health (Canada), American Well (US), GlobalMed (US), Care Innovations LLC (US), Honeywell International Inc. (US), InTouch Technologies Inc. (US), Medtronic PLC (Ireland), Philips Healthcare (Netherlands), Cerner Corporation (US), Dialogue (Canada), Maple (Canada), Cisco Systems Inc. (US), and Livecare Health (Canada).

 

Telehealth Market Segmentation

Global telehealth market report has been segmented into component, mode of delivery, application, and end user.

Global telehealth market analysis, by component, has been segregated into services, software, and hardware. The services segment accounted for the largest share owing to the increasing initiatives by key companies, whereas the software segment is expected to be the fastest-growing due to the growing inclination toward the usage of telehealth software. The market, by hardware, has been further sub-segmented into monitoring devices, medical peripherals, and others. The market, by monitoring devices, has been sub-segmented into stationary and wearable monitoring devices. The market, by medical peripherals, has been further divided into blood pressure monitors, ECG monitors, pulse oximeters, blood glucose meters, peak flow meters, otoscopes, and others. The market, by software, has been segregated into integrated software and standalone software. The market, by services, has been further classified as remote monitoring, real-time interactions, and store-and-forward consultations.

The global telehealth market, by mode of delivery, has been divided into web/cloud-based and on-premise. The web/cloud-based segment held a large share due to the wide preferability, whereas the on-premise segment is projected to be the fastest-growing due to the increasing awareness among hospital management.

The global telehealth market, by application, has been categorized as radiology, cardiology, primary care, neurophysiology, and others. The radiology segment held a major share owing to the increased use of telehealth technology in the radiology field, whereas the cardiology segment is projected to be the fastest growing owing to the rise in cardiovascular diseases.

The global telehealth market, by end user has been classified as hospitals and clinics, diagnostic clinics, home care, and others. Hospitals and clinics segment held a major share due to the increase in the number of hospitals employing the use of telehealth software, whereas the diagnostic clinics segment is expected to be the fastest-growing segment due to the rising inclination towards telehealth services.

Telehealth Market Regional Analysis

Global telehealth market share, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the global telehealth market. This can be attributed to the increasing adoption of telehealth services in the US. For instance, in 2016, Kaiser Permanente, an integrated managed care consortium based in California, conducted more consultations virtually than in person, i.e., nearly 52% of 110 million physician visits were via online portals, virtual visits, or apps.

The Europe market for telehealth is expected to be the second largest market. The paradigm shift toward more organized and continuous healthcare monitoring is projected to be the main factor for the growth of the market extensively. Italy held a share of 12.4% in the Western Europe telehealth market in 2018.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/report/covid-19-impact-telehealth-market

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the rise in geriatric population, an increase in the prevalence of chronic diseases, and the shortage of technical personnel.

The Middle East & Africa is expected to witness steady growth due to limited access and healthcare affordability among the population.

Covid-19 Impact On Health Insurance Market In-Depth Analysis With Current Trends And Future Estimations

 Market Scenario:

The Global Health Insurance Market is expected to register a CAGR of ~4.1% during the forecast period of 2019 to 2025 and will achieve USD 141.3 Billion in 2025 with a market value of USD 137.4 billion in 2018.

The increasing participation of key players is one of the key factors driving the health insurance market.

For example, Allianz Partners acquired 100% share capital of Servicios Compartidos Multiasistencia, SL from private equity funds managed by Portobello Capital, and marginal shareholders. Various other factors such as the increase in aging population and rise in health expenditure drive the growth of the market. In addition, rise in per capita disposable incomes of individuals and advancement in R&D in the field of medicine are also expected to propel the growth of the market. However, poor claim settlement track record and rigid rules hinder the market growth. The adoption of social media to create health awareness among the youth and research & development in pharmaceuticals is providing opportunities to increse the global health insurance market size.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8227

Segmentation

The global health insurance market is segmented based on demographics, type, term, service providers, and region.

The global market for health insurance, by demographics, has been divided into minor, adult and senior citizens. Adults aged 18–64, 69.0% (136.7 million) were covered by private health insurance plans in the first 9 months of 2018 in the US.

Based on type, the market has been segmented into health maintenance organizations (HMOs), exclusive provider organizations (EPOs), point-of-service (POS) plans, and preferred provider organizations (PPOs). A health maintenance organization (HMO), is a prepaid health plan. The health maintenance organization (HMO) member pays a monthly premium. In return, the health maintenance organization (HMO) offers wide-ranging health care facilities such as emergency care, hospital stays, surgery, laboratory (lab) tests, X-rays, doctor’s visits, and therapy

Based on the period, the market has been segregated into lifetime coverage and term insurance.  The Patient Protection and Affordable Care Act (PPACA) or Obamacare, abolished lifetime maximum benefit clauses in healthcare policies wherever they relate to essential services. The Affordable Care Act legislation also eliminates the facility for health care insurers to place yearly maximums on essential services such as ambulatory patient services, maternity, pregnancy, and neonatal care, laboratory services, and others.

Based on the service providers, the market has been bifurcated into public and private. The public health insurance has been further sub-categorized as Medicare and Medicaid. The private health insurance has been sub-segmented into primary private health insurance, duplicate private health insurance, complimentary private health insurance, and supplementary private health insurance. The number of Americans registered in private healthcare plans has increased from 12.8% to 34% between 2004 and 2017.

In the current scope of the study, the segments mentioned above are covered across four global regions, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The health insurance market in the Americas has further been segmented into North America and South America, with the North American market has been divided into the US and Canada. The European health insurance market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The health insurance market in Asia-Pacific has been categorized as Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The health insurance market in the Middle East & Africa has been segmented into the Middle East and Africa.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8227

Key Players

• Allianz SE
• IHI-Bupa
• William Russell
• Aetna
• Blue Cross
• Expacare
• CIGNA
• International SOS
• MediCare International
• Integra Global Health Limited
• HealthCare International
• MultiNational Underwriters

Regional Market Summary

The Americas dominated the global market for health insurance owing to the increasing awareness among the people about chronic diseases and many players are coming up with new insurance ideas for the welfare of the individuals. The percentage of people with health insurance coverage for 2017 was 91.2 % in the US. The US continues to be the largest contributor to the complete growth of health premiums worldwide, driven by the expansion of coverage implemented with the Affordable Care Act.

In 2018, it was estimated that Europe stood second in the global health insurance market. Technological advancements, along with the availability of funding opportunities in research and innovation will support the growth of health insurance during the review period. Other factors such as a favorable reimbursement scenario, rise in government expenditure on healthcare, and increase in geriatric population in this region can be attributed to the market growth.

Asia-Pacific (APAC) is expected to witness a phenomenal growth in health insurance throughout the forecast period due to rising participation of market players in launching innovative health insurance policies and the growing demand for the treatment of chronic diseases, lenient regulations, adoption of innovative technologies, and rise in medical tourism. The fastest-growing regional market in APAC, mostly fueled by the efforts of companies in China and India to increase health insurance penetration, with China concentrating on its aging population and India on its rural population. Net profit margins in APAC are also the highest globally, led by smaller regional markets such as Hong Kong and Singapore.

On the other hand, the Middle East & Africa holds the least share in the global health insurance market due to the low economic development, especially within the African region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/health-insurance-market-8227